How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

136,080 results for

Genetic Determinants of Drug Response

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

Angela M. Cheung, M.D., Ph.D. Senior Scientist Departments of Medicine and Medical Imaging of University of Toronto Toronto, Ontario, Canada Carolyn J. Crandall, M.D., M.S., FACP* Professor of Medicine David Geffen School of Medicine at University of California, Los Angeles Los Angeles, CA Andrea Z. LaCroix, Ph.D. Professor and Chief of Epidemiology Family Medicine and Public Health at University of California, San Diego San Diego, CA Eric S. Orwoll, M.D. Professor of Medicine Oregon Health & Science (...) , Los Angeles Los Angeles, CA Nancy Lane, M.D. Director and Distinguished Professor Center for Musculoskeletal Health and Department of Internal Medicine University of California at Davis, School of Medicine Sacramento, California Jasvinder Singh, M.D., M.P.H. Division of Rheumatology University of Alabama Birmingham, AL vii Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Structured Abstract Objective. To summarize the effects of long-term

2019 Effective Health Care Program (AHRQ)

2. Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients

Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients LABORATORY MEDICINE PRACTICE GUIDELINES EDITED BY LORALIE J. LANGMAN AND PAUL J. JANNETTO Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients Co-Sponsored byLABORATORY MEDICINE PRACTICE GUIDELINES Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients Loralie J. Langman Committee Chair Department of Laboratory Medicine and Pathology Mayo Clinic (...) References 101 Table of ContentsLABORATORY MEDICINE PRACTICE GUIDELINES Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients 5 Executive Summary Introduction The American Association for Clinical Chemistry (AACC) Acad- emy, formerly the National Academy of Clinical Biochemistry (NACB), has developed a laboratory medicine practice guidelines (LMPG) for using laboratory tests to monitor drug therapy in pain management patients. The scope and purpose of this guideline

2018 American Academy of Pain Medicine

3. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

rheumatoid arthritis with strength of evidence grades 117 Figures Figure 1. Analytic framework for drug therapy for early rheumatoid arthritis 6 Figure 2. Summary of literature search flow and yield for early rheumatoid arthritis 16 Figure 3. Network diagram for network meta-analysis: ACR50 response rates 41 Figure 4. Network diagram for network meta-analysis: change from baseline in radiographic joint damage score 41 vii Figure 5. Forest plot for network meta-analysis of ACR50 response rates: MTX plus (...) cross appreciable benefits or harms ES-13 Outcome Type Specific Outcome Results Strength of Evidence Summary of Rationale for Strength of Evidence Harms SAEs and D/C attributable to AEs TNF biologic (ADA or ETN) compared with non-TNF biologic (RIT) 8 Insufficient Downgraded because no ITT analysis; large CIs cross appreciable benefits or harms; and not enough events to meet optimal information size a Response defined by ACR or DAS28. b Strength of evidence grade applies to each specific drug therapy

2018 Effective Health Care Program (AHRQ)

4. CRACKCast E179 – Drug Therapy in Pregnancy

are some “D” drugs Amiodarone All NSAIDS in the 3rd trimester Carbamazepine Paroxetine Sulfonamides Tetracyclines [3] List 5 dangerous medicines to be avoided if breastfeeding Concerns exist for: Amiodarone Chemotherapeutic/antineoplastic agents Chloramphenicol Ergotamine Gold salts Phenindione Radioactive pharmaceuticals Retinoids Tetracyclines (chronic > 3 weeks) Certain psychotropic medications Codeine Pseudoephedrine Copied from: For more resources on this, see: [4] List 4 dangerous antibiotics (...) Concepts Chemically induced birth defects are believed to be responsible for approximately 1% to 3% birth defects. Gestational age is crucial in determination of the impact of any given exposure, especially during organogenesis (days 21–56 of fetal life), when major body organs are formed. Human data on teratogenicity and fetal toxicity of medications is often limited, and causal associations are difficult to determine, especially with newer medications. In general, the health of the fetus is directly

2018 CandiEM

5. Functional Family Therapy (FFT) for Young People in Treatment for Non?opioid Drug Use: A Systematic Review Full Text available with Trip Pro

, but there is a need to synthesize individual study results for specific family therapies to determine whether and to what extent specific family therapy interventions work for young drug abusers ( ; ; ; ; ). This review is concerned specifically with Functional Family Therapy (hereafter FFT) ( ; ; ), as aggregated evidence for the effects of this approach is lacking. The review will seek to clarify the effects of the FFT program for relevant groups of young people aged 11‐21, and will focus on young people (...) Functional Family Therapy (FFT) for Young People in Treatment for Non?opioid Drug Use: A Systematic Review Functional Family Therapy (FFT) for Young People in Treatment for Non‐opioid Drug Use: A Systematic Review - Filges - 2015 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Functional Family Therapy (FFT) for Young People

2015 Campbell Collaboration

6. Family Behavior Therapy (FBT) for Young People in Treatment for Non?opioid Drug Use: A Systematic Review Full Text available with Trip Pro

individual study results for specific family therapies to determine whether and to what extent specific family therapy interventions work for young drug users ( ; ; ; ; ). This review explores the specific family‐based intervention Family Behavior Therapy (FBT) ( ; ; ). The review attempts to clarify the effects of the FBT program for relevant groups of young people aged 11‐21 years. It focuses on young people enrolled in treatment for drug use regardless of how their problem is labeled. Enrolment (...) Family Behavior Therapy (FBT) for Young People in Treatment for Non?opioid Drug Use: A Systematic Review Family Behavior Therapy (FBT) for Young People in Treatment for Non‐opioid Drug Use: A Systematic Review - Lindstrøm - 2015 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Family Behavior Therapy (FBT) for Young People in Treatment

2015 Campbell Collaboration

7. Multidimensional Family Therapy (MDFT) for Young People in Treatment for Non?opioid Drug Abuse: A Systematic Review Full Text available with Trip Pro

integrated into a comprehensive treatment approach to meet the unique needs of young drug abusers (ibid. 23). A number of studies and reviews show positive results for family therapies in general, but there is a need to synthesize individual study results for specific family therapies to determine whether and to what extent specific family therapy interventions work for young drug abusers ( ; ; ; ; ). This review has explored the specific family‐based intervention of Multidimensional Family Therapy (MDFT (...) Multidimensional Family Therapy (MDFT) for Young People in Treatment for Non?opioid Drug Abuse: A Systematic Review Multidimensional Family Therapy (MDFT) for Young People in Treatment for Non‐opioid Drug Abuse: A Systematic Review - Filges - 2015 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Multidimensional Family Therapy (MDFT

2015 Campbell Collaboration

8. Genome-wide association study: Exploring the genetic basis for responsiveness to ketogenic dietary therapies for drug-resistant epilepsy. Full Text available with Trip Pro

Genome-wide association study: Exploring the genetic basis for responsiveness to ketogenic dietary therapies for drug-resistant epilepsy. With the exception of specific metabolic disorders, predictors of response to ketogenic dietary therapies (KDTs) are unknown. We aimed to determine whether common variation across the genome influences the response to KDT for epilepsy.We genotyped individuals who were negative for glucose transporter type 1 deficiency syndrome or other metabolic disorders (...) , who received KDT for epilepsy. Genotyping was performed with the Infinium HumanOmniExpressExome Beadchip. Hospital records were used to obtain demographic and clinical data. KDT response (≥50% seizure reduction) at 3-month follow-up was used to dissect out nonresponders and responders. We then performed a genome-wide association study (GWAS) in nonresponders vs responders, using a linear mixed model and correcting for population stratification. Variants with minor allele frequency <0.05 and those

2018 Epilepsia

9. Transcranial Direct Current Stimulation (tDCS) Cost-utility-analysis in Medical Care on Depressive Episode With One Drug Therapy Failure.

Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Transcranial Direct Current Stimulation (tDCS) Cost-utility-analysis in Medical Care on Depressive Episode With One Drug Therapy Failure. (DISCO) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health (...) Transcranial Direct Current Stimulation (tDCS) Cost-utility-analysis in Medical Care on Depressive Episode With One Drug Therapy Failure. Transcranial Direct Current Stimulation (tDCS) Cost-utility-analysis in Medical Care on Depressive Episode With One Drug Therapy Failure. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2018 Clinical Trials

10. Cognitive?Behavioural Therapies for Young People in Outpatient Treatment for Non?Opioid Drug Use: A Systematic Review Full Text available with Trip Pro

is perceived as a complex, multi‐determined, cognitive and behavioural pattern influenced by several domains, including family history, environmental genetic factors, and comorbid psychopathologies that all play a contributing role in the development of and/or perpetuation of drug use ( ). The primary focus of CBT is on reducing users' positive expectations about drug use, enhancing their self‐confidence to resist drugs, and improving their problem‐solving skills and skills for coping with daily life (...) report on the treatment process in a separate article ( ). In the following paragraphs, this study is cited as , ). This study compared Cognitive‐Behavioural Therapy (CBT) and Psychoeducational Therapy (PET) in a two‐armed RCT. The results of the trial are reported in Kaminer, Burleson, & Goldberger (2002) and this study is cited in the following paragraphs as . This is a two‐armed RCT comparing Integrated Family and Cognitive‐Behavioural Therapy (IFCBT) and Drugs Harm Psychoeducational curriculum

2015 Campbell Collaboration

11. Brief Strategic Family Therapy (BSFT) for Young People in Treatment for Non?Opioid Drug Use: A Systematic Review Full Text available with Trip Pro

for family therapies in general, but there is a need to synthesize individual study results for specific family therapies to determine whether and to what extent specific family therapy interventions work for young drug users ( ; ; ; ; ). This review is concerned specifically with Brief Strategic Family Therapy ( ; ) as a strong body of evidence on the effects of this form of family‐based intervention is sorely lacking. This review has attempted to clarify the effects of the BSFT program for relevant (...) Brief Strategic Family Therapy (BSFT) for Young People in Treatment for Non?Opioid Drug Use: A Systematic Review Brief Strategic Family Therapy (BSFT) for Young People in Treatment for Non‐Opioid Drug Use: A Systematic Review - Lindstrøm - 2013 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Brief Strategic Family Therapy (BSFT

2013 Campbell Collaboration

12. Prediction of response to drug therapy in psychiatric disorders Full Text available with Trip Pro

Prediction of response to drug therapy in psychiatric disorders Personalized medicine has become increasingly relevant to many medical fields, promising more efficient drug therapies and earlier intervention. The development of personalized medicine is coupled with the identification of biomarkers and classification algorithms that help predict the responses of different patients to different drugs. In the last 10 years, the Food and Drug Administration (FDA) has approved several genetically (...) pre-screened drugs labelled as pharmacogenomics in the fields of oncology, pulmonary medicine, gastroenterology, haematology, neurology, rheumatology and even psychiatry. Clinicians have long cautioned that what may appear to be similar patient-reported symptoms may actually arise from different biological causes. With growing populations being diagnosed with different psychiatric conditions, it is critical for scientists and clinicians to develop precision medication tailored to individual

2018 Open biology

13. Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contrai

Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contrai October 2019 EUnetHTA Joint Action 3 WP4 1 EUnetHTA Joint Action 3 WP4 Version 1.0, 22/10/2019 Relative effectiveness assessment of pharmaceutical technologies USTEKINUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE (...) and Pharmaceutical Benefits Agency (TLV). Relative effectiveness assessment of pharmaceutical technologies. Ustekinumab for the treat- ment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies. EUnetHTA Project ID: PTJA07. 2019. PTJA07 - Ustekinumab for active ulcerative colitis October 2019 EUnetHTA Joint Action 3

2020 EUnetHTA

14. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing Full Text available with Trip Pro

Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing Resistance-associated variant (RAV) is one of the most significant clinical challenges in treating HCV-infected patients with direct-acting antivirals (DAAs). We investigated the viral dynamics in patients receiving DAAs using third-generation sequencing technology. Among 283 patients with genotype-1b HCV receiving (...) daclatasvir + asunaprevir (DCV/ASV), 32 (11.3%) failed to achieve sustained virological response (SVR). Conventional ultra-deep sequencing of HCV genome was performed in 104 patients (32 non-SVR, 72 SVR), and detected representative RAVs in all non-SVR patients at baseline, including Y93H in 28 (87.5%). Long contiguous sequences spanning NS3 to NS5A regions of each viral clone in 12 sera from 6 representative non-SVR patients were determined by third-generation sequencing, and showed the concurrent

2017 Scientific reports

15. Magnesium as a Mediator of Bone and Vitamin D Metabolism in Patients on Antiepileptic Drug Therapy

one or more studies before adding more. Magnesium as a Mediator of Bone and Vitamin D Metabolism in Patients on Antiepileptic Drug Therapy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03471481 Recruitment Status (...) : Recruiting First Posted : March 20, 2018 Last Update Posted : August 9, 2018 See Sponsor: Drexel University Information provided by (Responsible Party): Drexel University Study Details Study Description Go to Brief Summary: The objective of this study is to determine the role of magnesium on bone and vitamin D metabolism in patients receiving anti-epileptic medications. Condition or disease Intervention/treatment Epilepsy Magnesium Deficiency Vitamin D Deficiency Other: No Intervention. Study is Cross

2018 Clinical Trials

16. Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

or more studies before adding more. Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma (MiST) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03654833 Recruitment Status (...) the genomic basis of drug response in the MiST trial, archival tumour tissue from all patients enrolled will be interrogated using molecular inversion probe- based microarray analysis of the somatic copy number aberrations. Optional re-biopsy of patients who progress on treatment, followed confirmed radiological response, will be offered, to investigate genomic interrogation of tumours at the time of acquired resistance. For arms 3 and 4, immune checkpoint, transcriptomic and gut microbiome correlative

2018 Clinical Trials

17. Safety and Therapeutic Drug Monitoring of Cefazolin in Continuous Renal Replacement Therapy

studies before adding more. Safety and Therapeutic Drug Monitoring of Cefazolin in Continuous Renal Replacement Therapy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03672149 Recruitment Status : Not yet recruiting First (...) of the Safety and Therapeutic Drug Monitoring of Continuous Infusion Cefazolin Through the Addition of the Cefazolin Into the Continuous Renal Replacement Therapy Solution. Estimated Study Start Date : January 1, 2019 Estimated Primary Completion Date : December 31, 2021 Estimated Study Completion Date : December 31, 2021 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Infection needing cefazolin a) If a patient requires

2018 Clinical Trials

18. Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting

Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting (SHARP-P) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal (...) ) therapy and reinfection in people with chronic hepatitis C virus (HCV) and recent injecting drug use. A prospective, observational cohort design will be used to enrol patients from correctional centres in New South Wales, Australia. Participants will be prescribed a direct-acting HCV medication as per the standard of care. The on treatment phase will vary dependent on the type of a direct-acting antiviral prescribed as per the standard of care. Once patients have completed their treatment course

2018 Clinical Trials

19. Early Evaluation of the Brown Glaucoma Implant in Patients Refractory to Drug Therapy in the European Union

(100). Please remove one or more studies before adding more. Early Evaluation of the Brown Glaucoma Implant in Patients Refractory to Drug Therapy in the European Union (EARLY BIRD EU) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov (...) Early Evaluation of the Brown Glaucoma Implant in Patients Refractory to Drug Therapy in the European Union Early Evaluation of the Brown Glaucoma Implant in Patients Refractory to Drug Therapy in the European Union - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2018 Clinical Trials

20. Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema

studies (100). Please remove one or more studies before adding more. Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03759860 Recruitment Status : Active, not recruiting First Posted (...) Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>